Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease

Pharmacogenomics Journal

Volumn 6, Issue 2, 2006, Pages 95-104

  Fumagalli, Fabio ^a   Racagni, G ^a,b   Riva, M A ^a  

^a Center of Neuropharmacology   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

Cognition; Dopaminergic system; Lifestyle; Neurodegenerative disorders; Neurotrophins

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); AMPA RECEPTOR; AMPA RECEPTOR AGONIST; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMOCRIPTINE; CHOLINERGIC RECEPTOR; DOPAMINE; DOPAMINE RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; GPI 1485; HERBACEOUS AGENT; ION CHANNEL; LADOSTIGIL; LEVODOPA; LY 503430; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN; NICOTINE; OXYGENASE; PRAMIPEXOLE; RASAGILINE; SELEGILINE; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ALZHEIMER DISEASE; BIOSYNTHESIS; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; EVIDENCE BASED PRACTICE; GENETIC ANALYSIS; HUMAN; HYDROGEL; INCIDENCE; LIFESTYLE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SUBSTANTIA NIGRA; UPREGULATION;

ANTIPARKINSON AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; PARKINSON DISEASE;

EID: 33645068212     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500360     Document Type: Review

References (134)

1. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005; 62: 353-357.
2. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004; 1: 139-154.
3. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Brain Res Rev 2000; 33: 199-227.
4. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 1994; 342: 321-334.
5. Porritt MJ, Batchelor PE, Howells DW. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 2005; 192: 226-234.
6. Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005; 25: 6251-6259.
7. Fumagalli F, Racagni G, Colombo E, Riva MA. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatr 2003a; 8: 898-899.
8. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain Res Rev 1998; 26: 148-153.
9. Cyr M, Beaulieu JM, Laakso A, Sotnikova TD, Yao WD, Bohn LM et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci 2003; 100: 11035-11040.
10. Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp Neurol 2001; 170: 121-128.
11. Dluzen DE, Anderson LI, McDermott JL, Kucera J, Walro JM. Striatal dopamine output is compromised within +/- BDNF mice. Synapse 2002; 43: 112-117.
12. von Bohlen Und Halbach O, Minichiello L, Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J 2005 Jul 21; [Epub ahead of print].
13. Kohno R, Sawada H, Kawamoto Y, Uemura K, Shibasaki H, Shimohama S. BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem Biophys Res Commun 2004; 318: 113-118.
14. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 1999; 270: 45-48.
15. Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, Hirsch E et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport 1999; 10: 557-561.
16. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000; 166: 127-135.
17. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000; 60: 277-290.
18. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
19. Hong CJ, Liu HC, Liu TY, Lin CH, Cheng CY, Tsai SJ. Related Articles, Links Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci Lett 2003; 353: 75-77.
20. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 2003; 250(Suppl 3): III40-III43.
21. Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR et al. The BDNF Val(66)Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 2005; 252: 833-838.
22. Hakansson A, Melke J, Westberg L, Shahabi HN, Buervenich S, Carmine A et al. Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann Neurol 2003; 53: 823.
23. Liu QR, Walther D, Drgon T, Polesskaya O, Lesnick TG, Strain KJ et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 93-103.
24. Betz AL, Goldstein GW, Katzman R. Blood-brain-cerebrospinal fluid barriers. In: Siegel G, Agranoff B, Albers RW, Molinoff P (eds). Basic Neurochemistry. Raven press: New York, 1989, pp. 591-606.
25. Knusel B, Beck KD, Winslow JW, Rosenthal A, Burton LE, Widmer HR et al. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci 1992; 12: 4391-4402.
26. Yan Q, Matheson C, Sun J, Radeke MJ, Feinstein SC, Miller JA. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp Neurol 1994; 127: 23-36.
27. Martinez-Serrano A, Bjorklund A. Immortalized neural progenitor cells for CNS gene transfer and repair. Trends Neurosci 1997; 20: 530-538.
28. Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003; 2: 437-445.
29. Kordower JH, Sortwell CE. Neuropathology of fetal nigra transplants for Parkinson's disease. Prog Brain Res 2000; 127: 333-344.
30. Tuszynski MH. Gene therapy for neurological disease. Expert Opin Biol Ther 2003; 3: 815-828.
31. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995; 15: 7810-7820.
32. Galpern WR, Frim DM, Tatter SB, Altar CA, Beal MF, Isacson O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 1996; 5: 225-232.
33. Hung HC, Lee EH. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 1996; 41: 14-26.
34. Jain A, Kim YT, McKeon RJ, Bellamkonda RV. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2005 [Epub ahead of print].
35. Thoenen H, Sendtner M. Neurotrophins: From enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002; 5 Suppl: 1046-1050.
36. Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience 1999; 93: 1491-1506.
37. Lahteinen S, Pitkanen A, Saarelainen T, Nissinen J, Koponen E, Castren E. Decreased BDNF signalling in transgenic mice reduces epileptogenesis. Eur J Neurosci 2002; 15: 721-734.
38. Lahteinen S, Pitkanen A, Koponen E, Saarelainen T, Castren E. Exacerbated status epilepticus and acute cell loss, but no changes in epileptogenesis, in mice with increased brain-derived neurotrophic factor signaling. Neuroscience 2003; 122: 1081-1092.
39. Okazawa H, Murata M, Watanabe M, Kamei M, Kanazawa I. Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 1992; 313: 138-142.
40. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86-89.
41. Ryoo HL, Pierrotti D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord 1998; 13: 788-797.
42. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-860.
43. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004; 18: 1471-1473.
44. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005; 48: 379-387.
45. Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today 2005a; 41: 369-391.
46. Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005; 26: 27-35.
47. Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 2003; 86: 290-297.
48. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004; 89: 1119-1125.
49. Ahlskog JE. Parkinson's disease: Is the initial treatment established? Curr Neurol Neurosci Rep 2003; 3: 289-295.
50. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20: 602-610.
51. Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2004; 2: 22.
52. Presgraves SP, Borwege S, Millan MJ, Joyce JN. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol 2004; 190: 157-170.
53. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-595.
54. Fumagalli F, Bedogni F, Maragnoli ME, Gennarelli M, Perez J, Racagni G et al. Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus. J Neurosci Res 2003b; 74: 74-80.
55. Takayama H, Ray J, Raymon HK, Baird A, Hogg J, Fisher LJ et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1995; 1: 53-58.
56. Grothe C, Schulze A, Semkova I, Muller-Ostermeyer F, Rege A, Wewetzer K. The high molecular weight fibroblast growth factor-2 isoforms (21 000 mol. Wt and 23 000 mol. wt) mediate neurotrophic activity on rat embryonic mesencephalic dopaminergic neurons in vitro. Neuroscience 2000; 100: 73-86.
57. Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Rev 2004; 47: 126-144.
58. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4: 277-282.
59. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273-276.
60. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-258.
61. O'Neill MJ, Murray TK, Clay MP, Lindstrom T, Yang CR, Nisenbaum ES. LY503430: Pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. CNS Drug Rev 2005; 11: 77-96.
62. Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D et al. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. J Pharmacol Exp Ther 2003; 306: 752-762.
63. Feeley Kearney JA, Albin RL. mGluRs: A target for pharmacotherapy in Parkinson disease. Exp Neurol 2003; 184(Suppl 1): S30-6.
64. Campusano JM, Abarca J, Forray MI, Gysling K, Bustos G. Modulation of dendritic release of dopamine by metabotropic glutamate receptors in rat substantia nigra. Biochem Pharmacol 2002; 63: 1343-1352.
65. Matarredona ER, Santiago M, Venero JL, Cano J, Machado A. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 2001; 76: 351-360.
66. Bond A, O'Neill MJ, Hicks CA, Monn JA, Lodge D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport 1998; 9: 1191-1193.
67. Battaglia G, Bruno V, Ngomba RT, Di Grezia R, Copani A, Nicoletti F. Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur J Pharmacol 1998; 356: 271-274.
68. Vincent AM, Mohammad Y, Ahmad I, Greenberg R, Maiese K. Metabotropic glutamate receptors prevent nitric oxide-induced programmed cell death. J Neurosci Res 1997; 50: 549-564.
69. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 1995; 45: 1041-1051.
70. Baron JA. Beneficial effects of nicotine and cigarette smoking: The real, the possible and the spurious. Br Med Bull 1996; 52: 58-73.
71. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav Brain Res 2000; 113: 117-120.
72. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002; 23: 581-594.
73. Allam MF, Campbell MJ, Del Castillo AS, Fernandez-Crehuet Navajas R. Related Articles, Links Parkinson's disease protects against smoking? Behav Neurol 2004; 15: 65-71.
74. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004; 27: 561-568.
75. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: A case-control study. Neurology 2000; 55: 1350-1358.
76. Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson disease: 1. Comparison of cases with matched neighbors. Neurology 1980; 30: 839-843.
77. Conti-Tronconi BM, McLane KE, Raftery MA, Grando SA, Protti MP. The nicotinic acetylcholine receptor: Structure and autoimmune pathology. Crit Rev Biochem Mol Biol 1994; 29: 69-123.
78. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4: 1224-1229.
79. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord 1998; 13: 637-642.
80. Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther 1999; 290: 731-739.
81. Quik M, Di Monte DA. Nicotine administration reduces striatal MPP+ levels in mice. Brain Res 2001; 917: 219-224.
82. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71: 2439-2446.
83. French SJ, Humby T, Horner CH, Sofroniew MV, Rattray M. Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Brain Res Mol Brain Res 1999; 67: 124-136.
84. Kenny PJ, File SE, Rattray M. Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res Mol Brain Res 2000; 85: 234-238.
85. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson's disease. Brain Cogn 2000; 43: 274-282.
86. Sacco KA, Bannon KL, George TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 2004; 18: 457-474.
87. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimer's and Parkinson's disease. Implications for therapeutics. Drugs Aging 1997; 11: 206-228.
88. Guo X, Dawson VL, Dawson TM. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 2001; 13: 1683-1693.
89. Ross DT, Guo H, Howorth P, Chen Y, Hamilton GS, Steiner JP. The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats. Neurosci Lett 2001; 297: 113-116.
90. Zhang C, Steiner JP, Hamilton GS, Hicks TP, Poulter MO. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J Neurosci 2001; 21: RC156.
91. Tanaka K, Fujita N, Ogawa N. Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain. Brain Res 2003; 970: 250-253.
92. Nitta A, Nishioka H, Fukumitsu H, Furukawa Y, Sugiura H, Shen L et al. Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. J Neurosci Res 2004; 78: 250-258.
93. Poulter MO, Payne KB, Steiner JP. Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004; 128: 1-6.
94. Sauer H, Francis JM, Jiang H, Hamilton GS, Steiner JP. Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice. Brain Res 1999; 842: 109-118.
95. Li FQ, Cheng XX, Liang XB, Wang XH, Xue B, He QH et al. Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons. Exp Neurol 2003; 179: 28-37.
96. Richmond TD, Chohan M, Barber DL. Turning cells red: Signal transduction mediated by erythropoietin. Trends Cell Biol 2005; 15: 146-155.
97. Aydin A, Genc K, Akhisaroglu M, Yorukoglu K, Gokmen N, Gonullu E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev 2003; 25: 494-498.
98. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002; 99: 9450-9455.
99. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
100. Zhang J, Li Y, Cui Y, Chen J, Lu M, Elias SB et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005; 1034: 34-39.
101. Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004; 91: 900-910.
102. Genc S, Kuralay F, Genc K, Akhisaroglu M, Fadiloglu S, Yorukoglu K et al. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production. Neurosci Lett 2001; 298: 139-141.
103. Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002; 321: 73-76.
104. Viviani B, Bartesaghi S, Corsini E, Villa P, Ghezzi P, Garau A et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem 2005; 93: 412-421.
105. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001; 13: 1529-1536.
106. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-2995.
107. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913.
108. Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol 2003; 93: 66-70.
109. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57: 2108-2111.
110. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis 2005; 19: 96-107.
111. Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 2005; 93: 802-811.
112. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study. Ann Neurol 1996; 39: 89-94.
113. Reuter I, Engelhardt M, Stecker K, Baas H. Therapeutic value of exercise training in Parkinson's disease. Med Sci Sports Exerc 1999; 31: 1544-1549.
114. Smidt N, de Vet HC, Bouter LM, Dekker J, Excercise Therapy Group. Effectiveness of exercise therapy: A best-evidence summary of systematic reviews. Aust J Physiother 2005; 51: 71-85.
115. van Praag H, Shubert T, Zhao C, Gage FH J. Exercise Enhances Learning and Hippocampal Neurogenesis in Aged Mice Neurosci. J Neurosci 2005; 25: 8680-8685.
116. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci USA 2004; 101: 18171-18176.
117. Bezard E, Dovero S, Belin D, Duconger S, Jackson-Lewis V, Przedborski S et al. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: Involvement of dopamine transporter and trophic factors. J Neurosci 2003; 23: 10999-11007.
118. Faherty CJ, Raviie Shepherd K, Herasimtschuk A, Smeyne RJ. Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism. Brain Res Mol Brain Res 2005; 134: 170-179.
119. Gomez-Pinilla F, Ying Z, Roy RR, Molteni R, Edgerton VR. Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. J Neurophysiol 2002; 88: 2187-2195.
120. Vaynman S, Ying Z, Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur J Neurosci 2004; 20: 2580-2590.
121. Ding Y, Li J, Luan X, Ding YH, Lai Q, Rafols JA et al. Exercise pre-conditioning reduces brain damage in ischemic rats that may be associated with regional angiogenesis and cellular overexpression of neurotrophin. Neuroscience 2004; 124: 583-591.
122. Poulton NP, Muir GD. Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats. Exp Neurol 2005; 193: 181-197.
123. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
124. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004; 21: 1457-1467.
125. Brown AM, Deutch AY, Colbran RJ. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci 2005; 22: 247-256.
126. Ivkovic S, Polonskaia O, Farinas I, Ehrlich ME. Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: Studies in vivo and in vitro. Neuroscience 1997; 79: 509-516.
127. Stroppolo A, Guinea B, Tian C, Sommer J, Ehrlich ME. Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro. J Neurochem 2001; 79: 1027-1032.
128. Blanquet PR, Mariani J, Derer P. A calcium/calmodulin kinase pathway connects brain-derived neurotrophic factor to the cyclic AMP-responsive transcription factor in the rat hippocampus. Neuroscience 2003; 118: 477-490.
129. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005 Jul 11; [Epub ahead of print].
130. Onyango IG, Tuttle JB, Bennett Jr JP. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H(2)O(2)-induced neuronal death. Neurobiol Dis 2005; 20: 141-154.
131. Nagappan G, Lu B. Activity-dependent modulation of the BDNF receptor TrkB: Mechanisms and implications. Trends Neurosci 2005; 28: 464-471.
132. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatr 2000; 24: 881-888.
133. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-357.
134. Mutoh T, Sobue G, Hamano T, Kuriyama M, Hirayama M, Yamamoto M et al. Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis. Neurochem Res 2000; 25: 239-245.